Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.47 USD
Change Today +0.03 / 1.23%
Volume 532.6K
SNSS On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Adam R. Craig M.D., Ph.D., M.B.A.

Chief Medical Officer and Executive Vice President of Development, Sunesis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 4 different industries.

As of Fiscal Year 2013


Dr. Adam R. Craig, MD, PhD, MBA has been Executive Vice President of Development and Chief Medical Officer at Sunesis Pharmaceuticals Inc., since March 1, 2012. Dr. Craig oversees the ongoing pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia (AML) and direct Sunesis' global development program. Dr. Craig has over 15 years of experience in hematology, oncology and clinical development. He served as Chief Medical ...

Read Full Background

Corporate Headquarters*

395 Oyster Point Boulevard
South San Francisco, California 94080

United States

Phone: 650-266-3500
Fax: 650-266-3501

Board Members Memberships*

There is no Board Members Memberships data available.


Bachelor's Degree 1999
University Of London
MD 1999
University Of London
PhD 2001
University of Leeds Medical School
Open University Business School

Other Affiliations*

Annual Compensation*

Total Annual Compensation$408,750

Stock Options*

All Other Compensation$3,130
Exercisable Options301,041
Exercisable Options Value$825,000
Unexercisable Options423,959
Unexercisable Options Value$975,000
Total Value of Options$1,800,000
Total Number of Options725,000

Total Compensation*

Total Annual Cash Compensation$575,880
Total Short Term Compensation$408,750
Other Long Term Compensation$3,130
Total Calculated Compensation$1,058,318
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNSS:US $2.47 USD +0.03


John R. Plachetka Pharm D.Co-Founder, Chairman, Chief Executive Officer and President
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at